MicroPort Orthopedics Celebrates 20 Years of Stability with its Medial-Pivot Total Knee System
MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting-edge joint replacement implants designed to help patients achieve full function faster, is celebrating 20 years of market experience with its medial-pivot total knee system. Since launching in 1998, over 550,000 patients have benefited from MicroPort’s medial-pivot technology, which touts compelling long-term clinical results.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306005995/en/
The Evolution® Medial-Pivot Knee System features medial ball-in-socket articulation and a mobile lateral compartment that pivots about the medial side, enhancing stability, providing high flexion, and allowing the prosthesis to replicate the natural feel and motion of the knee. (Photo: Business Wire)
“The medial-pivot knee system has now stood the test of time at 20 years demonstrating impressive survivorship and excellent patient satisfaction,” said C. Lowry Barnes, MD, Chair of Orthopedic Surgery at the University of Arkansas for Medical Sciences. “It is important to recognize that this isn’t just one single publication. Over the years, the Advance® and Evolution® Medial-Pivot Knee Systems have been included in over 90 peer-reviewed publications that validate its long-term durability and functionality.”
For many years, orthopedists have clung to the concept of a hinge-like knee design with multiple radii. However, studies show that on average, 20% of patients are not satisfied with the outcome of their total knee replacement. Challenging these traditional knee designs, pioneers such as J. David Blaha, MD, Mr. Michael Freeman, MD, and Richard Komistek, PhD provided kinematic and radiographic evidence supporting medial-pivoting kinematics and stability of the knee, paving the way for the release of MicroPort’s medial-pivot knee system.
“I began using MicroPort’s medial-pivot knee system in May of 1998,” said Joost Lagast, MD, Orthopedic Surgeon at Maria Middelares Hospital Ghent. “At the time, I was not 100% satisfied with my results and was looking for something new. I attended a meeting with Professor Blaha at AAOS and was very impressed with the medial-pivot concept. During my first case, it was love at first sight – the stability and natural motion were unlike anything I’d seen in my practice. Over the last 20 years, I’ve performed nearly 4,000 knee replacement surgeries using the system, and I’m still fantastically in love with it today.”
The Evolution® Medial-Pivot Knee System features medial ball-in-socket articulation and a mobile lateral compartment that pivots about the medial side, enhancing stability, providing high flexion, and allowing the prosthesis to replicate the natural feel and motion of the knee. Additionally, the medial stability of the Evolution® knee substitutes for both the ACL and PCL, allowing for normal quadriceps function and increased proprioception.
Former NFL quarterback and Hall-of-Famer, Terry Bradshaw, underwent total knee replacement surgery with the Evolution® Medial-Pivot Knee. “My knee was causing me all kinds of problems. I couldn’t sleep at night, I couldn’t take the stairs, and worst of all, I had a hard time playing with my granddaughter,” said Bradshaw, now 69 years old. “I underwent surgery on a Tuesday, left the hospital two days later, and was walking without assistance in two weeks. Today, I can do anything I want to do – walking down stairs, squatting, fishing, and golfing. The medial-pivot technology has been life changing for me. It feels just like my knee!”
“MicroPort Orthopedics is proud to celebrate the 20th anniversary of our medial-pivot knee system,” said Aurelio Sahagun, President, MicroPort Orthopedics. “When we launched the system back in 1998, there was nothing else like it on the market – it challenged the basis of traditional designs. Change does not happen often in orthopedics, but at the time, we knew that the medial-pivot concept had the capability to revolutionize total knee replacement. 20 years later, clinical results have proven that this design delivers better outcomes for patients and surgeons. It is incredibly gratifying to offer a best-in-class knee replacement option, and we are looking forward to another 20 years of innovation as we expand the medial-pivot technology into the revision market.”
About MicroPort Orthopedics
Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.
About MicroPort Scientific
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
Alex Piersiak, 617-909-5022
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Greene Tweed Receives Patent for Rapid Gas Decompression-Resistant Fluoroelastomers and Molded Articles24.10.2018 00:00 | Tiedote
The U.S. Patent Office has awarded Greene Tweed Patent Number 10,011,690 for Rapid Gas Decompression-Resistant Fluoroelastomer Compositions and Molded Articles. The innovative elastomer technology was developed by a team that included inventor Ron Campbell, PhD, Principal Scientist and Technology Leader for Elastomers in Greene Tweed’s Advanced Technology Group, to provide a competitive advantage in the Energy market and expand technology protected under a previous patent. Rapid gas decompression (RGD) often occurs when high-pressure gas molecules migrate into an elastomer at a compressed state. When the pressure surrounding the elastomer is suddenly released, the compressed gas inside the elastomer tries to expand and exit the elastomer, thus causing RGD (also known as explosive decompression). Most elastomers experience severe blistering or cracking when the force of these expanding gases overcome the strength of the surrounding material; however, materials engineered to withstand RG
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains23.10.2018 21:00 | Tiedote
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting good health outcomes. The results of a new study strengthen the evidence for this theory, showing that infant-type HRB may be able to break down incompletely digested peptides in the infants’ gastrointestinal systems and thus contribute to their overall health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005015/en/ Fig 1. Food-derived opioid peptides are potential risk factors for human health (Graphic: Business Wire) Human-Residential Bifidobacteria for Humans Morinaga Milk has been conducting research on bifidobacteria for many years, and studies over the past decades have shown that bifidobacteria play a vital role in various aspects of human health. There are two major groups of bifidobacteria: Human-Residential Bif
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 19:22 | Tiedote
Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope
Christo Georgiev Announces the Arrival of myPOS AppMarket23.10.2018 19:11 | Tiedote
myPOS Europe Ltd., a leading card payments provider to small and medium-sized businesses in Europe, is introducing its own AppMarket – an innovative software platform for business applications that allows myPOS clients to find, download and use various apps for improved business performance. The development of myPOS AppMarket was driven by the necessity to meet the ever-changing business needs dictated by customer demand and behaviour. While the payment terminals myPOS offers come with a large number of innovative payments features, there are other business needs which remain uncaptured at the moment. myPOS founder Mr. Christo Georgiev says: “Individual businesses need a tailored approach when it comes to accepting payments for their services. Offering a fully customizable and complete omni-channel payments solution, which empowers businesses to stay agile, has always been in our foresight. Tapping into the familiarity of our everyday favourite device – the smartphone, pushed us even f
CNIM Presents a Rapid Version of The LCAT® Shore-to-Shore Featuring Unique Operational Capabilities23.10.2018 18:45 | Tiedote
The L-CAT® Shore-to-shore presented by CNIM at Euronaval 2018 delivers a major increase in performance for amphibious missions. The L-CAT® Shore-to-shore has been upgrated since its launch 2 years ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005869/en/ CNIM's amphibious craft, the L-CAT® Shore-to-shore (Photo: CNIM) The L-CAT® Shore-to-shore is now the only vessel with the ability to transport 80 tonnes at 25 knots in conditions up to sea state 5, land in shallow water (~1m) and accommodate 42 passengers for long distance trips. Highly maneuvrable, the L-CAT® Shore-to-shore provides exceptional operational flexibility for amphibious assaults and humanitarian operations, without compromising between speed and payload. Its wide loading platform (145 m²), ability to travel up to 800 nautical miles when loaded, self-defence and communication capabilities are tactical advantages for the projection of Forces. Its spee
Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia23.10.2018 16:03 | Tiedote
Exterior Plus, the out-of-home advertising platform of H.I.G. Capital, announces the acquisition of Impactmedia (the “Company”), a leading shopping mall advertising company, with over 630 million viewers in high-traffic premium locations throughout Spain. This is a major step forward in Exterior Plus’s consolidation strategy, as it aims to become the Spanish leader in out-of-home advertising with a unique, diversified and highly-competitive product portfolio, reaching very diverse audiences at a national level. Impactmedia is an experienced leader in shopping mall advertising, offering digital advertising as well as special marketing actions. The Company operates in over 90 shopping centers where it has more than 1,200 digital displays. The acquisition allows Exterior Plus to gain a strong presence near points of sale, a key value driver for advertisers. H.I.G. Capital acquired and established the Exterior Plus group in December 2015. The group currently markets more than 25,000 advert
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme